In the present work, the first voltammetric method is developed for the detection of
pazopanib (PZB), a pharmaceutically active ingredient belonging to the tyrosine kinase …

Background Nivolumab plus ipilimumab (NIVO+ IPI) is the first‐line treatment for patients
with metastatic renal cell carcinoma (mRCC). Approximately 40% of patients achieve a …

Over the last decade, there have been substantial progress in the field of systemic therapy
for advanced renal cell carcinoma. Through the transition from treatment with cytokines to …

Background Nivolumab plus ipilimumab combination therapy is one of the standard
therapies for untreated renal cell carcinoma patients with an International Metastatic Renal …

Objectives This study aimed to assess the prognostic outcomes in mRCC patients receiving
second‐line TKI following first‐line IO combination therapy. Methods This study …

Objectives This study aims to evaluate the utility of the scoring system of the Registry for
Metastatic Renal Cell Carcinoma (REMARCC) model on the overall survival (OS) of patients …

Background Long-term follow-up data regarding treatment outcomes of nivolumab plus
ipilimumab combination therapy for advanced renal cell carcinoma as a first-line therapy are …

Background Nivolumab plus ipilimumab (NIVO+ IPI) is the first-line treatment for patients
with metastatic renal cell carcinoma (mRCC). While approximately 40% of patients treated …

Background Nivolumab and ipilimumab combination therapy is approved in Japan for
unresectable or metastatic renal cell carcinoma. Because the clinical trials supporting the …

Objectives To investigate the eligibility for maintenance immunotherapy and its impact on
the prognosis of advanced urothelial carcinoma treated with first‐line chemotherapy, as the …